HZNP | Horizon Therapeutics Public Limited Company Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	116.30 - 116.34
52 Week Range	116.30 - 116.34
Beta	1.00
Implied Volatility	7.81%
IV Rank	N/A
Day's Volume	23,917,757
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	26,632,068,258
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	2011-07-28

Valuation
Profitability
Growth
Health
P/E Ratio	61.86
Forward P/E Ratio	24.17
EPS	1.88
1YR Price Target	101.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2,190
Country	Ireland
Website	HZNP

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.

HZNP's peers: SCLX

*Chart delayed

Analyzing fundamentals for HZNP we got that it has average fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is very strong. For more detailed analysis please see HZNP Fundamentals page.

Watching at HZNP technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on HZNP Technicals page.